WO2005009436A8 - Dispersible formulation of an anti-inflammatory agent - Google Patents

Dispersible formulation of an anti-inflammatory agent

Info

Publication number
WO2005009436A8
WO2005009436A8 PCT/IB2004/002461 IB2004002461W WO2005009436A8 WO 2005009436 A8 WO2005009436 A8 WO 2005009436A8 IB 2004002461 W IB2004002461 W IB 2004002461W WO 2005009436 A8 WO2005009436 A8 WO 2005009436A8
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory agent
dispersible formulation
dispersible
organ
formulation
Prior art date
Application number
PCT/IB2004/002461
Other languages
French (fr)
Other versions
WO2005009436A1 (en
Inventor
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Original Assignee
Pharmacia & Upjohn Co Llc
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Nancy Jean Britten, Niki Ann Waldron, Jeffrey Lynn Watts, John Walter Hallberg, John William Ii Burns filed Critical Pharmacia & Upjohn Co Llc
Priority to AU2004258745A priority Critical patent/AU2004258745A1/en
Priority to MXPA06001288A priority patent/MXPA06001288A/en
Priority to JP2006521702A priority patent/JP2007500691A/en
Priority to EP04744112A priority patent/EP1651210A1/en
Priority to CA002533101A priority patent/CA2533101A1/en
Priority to BRPI0412581-9A priority patent/BRPI0412581A/en
Publication of WO2005009436A1 publication Critical patent/WO2005009436A1/en
Publication of WO2005009436A8 publication Critical patent/WO2005009436A8/en
Priority to IL172735A priority patent/IL172735A0/en
Priority to NO20060982A priority patent/NO20060982L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method is provided for treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as lthe udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and a process for preparing such a composition.
PCT/IB2004/002461 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent WO2005009436A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2004258745A AU2004258745A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent
MXPA06001288A MXPA06001288A (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent.
JP2006521702A JP2007500691A (en) 2003-07-31 2004-07-19 Dispersible formulation of anti-inflammatory agent
EP04744112A EP1651210A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent
CA002533101A CA2533101A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent
BRPI0412581-9A BRPI0412581A (en) 2003-07-31 2004-07-19 dispersible formulation of an anti-inflammatory agent
IL172735A IL172735A0 (en) 2003-07-31 2005-12-21 Dispersible formulation of an anti-inflammatory agent
NO20060982A NO20060982L (en) 2003-07-31 2006-02-28 Dispersant formulation for an anti-inflammatory agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
US60/492,121 2003-07-31

Publications (2)

Publication Number Publication Date
WO2005009436A1 WO2005009436A1 (en) 2005-02-03
WO2005009436A8 true WO2005009436A8 (en) 2005-05-06

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002461 WO2005009436A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent

Country Status (14)

Country Link
EP (1) EP1651210A1 (en)
JP (1) JP2007500691A (en)
KR (1) KR100780983B1 (en)
CN (1) CN1829510A (en)
AU (1) AU2004258745A1 (en)
BR (1) BRPI0412581A (en)
CA (1) CA2533101A1 (en)
CO (1) CO5650245A2 (en)
IL (1) IL172735A0 (en)
MX (1) MXPA06001288A (en)
NO (1) NO20060982L (en)
RU (1) RU2319508C2 (en)
WO (1) WO2005009436A1 (en)
ZA (1) ZA200600096B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (en) * 2006-12-20 2008-10-17 Schering Plough Ltd PHARMACEUTICAL COMPOSITIONS OF FLUNIXIN
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
UA111147C2 (en) * 2009-11-11 2016-04-11 Байєр Б.В. METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF EXTERNAL OTITIS
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
ES2391721T3 (en) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Transparent aqueous solutions of fluocinolone acetonide for the treatment of ear swelling
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
RU2486905C1 (en) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Method of treating mastitis in animals
CN102784161A (en) * 2012-08-01 2012-11-21 张吉川 Specific ear drops for treating acute/chronic tympanitis
CN104981253B (en) * 2013-01-14 2019-05-10 因佛斯特医疗有限公司 Solid solution composition and its purposes in chronic inflammation
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treatment of subclinical mastitis in cows
KR20180030416A (en) * 2015-08-05 2018-03-22 칠드런'즈 메디컬 센터 코포레이션 Composition with penetration enhancer for drug delivery
KR101738815B1 (en) * 2015-08-27 2017-05-23 심민보 Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus comprising platelet-rich plasma and method using the same
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
RU2749857C1 (en) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Method for combatting otitis media and otitis externa
RU2751697C1 (en) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Remedy for treatment of otitis of external auditory canal in dogs
KR102461699B1 (en) * 2021-05-21 2022-11-03 현대약품 주식회사 Gargle solution with improved stability comprising benzidamine hydrochloride
WO2023101418A1 (en) * 2021-12-03 2023-06-08 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus
KR20230084418A (en) * 2021-12-03 2023-06-13 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
DK1147766T3 (en) * 1994-10-26 2005-08-29 Novartis Ag Pharmaceutical compositions
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
DZ2479A1 (en) * 1997-05-05 2003-02-01 Pfizer Anti-inflammatory selective co-2 inhibitor compounds and pharmaceutical compositions containing them.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
CA2409123A1 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use
WO2001098362A2 (en) * 2000-06-16 2001-12-27 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
AU2001288322A1 (en) * 2000-09-12 2002-03-26 Pharmacia And Upjohn Company Llc Pharmaceutical composition having specific water activity
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
BRPI0412581A (en) 2006-09-19
WO2005009436A1 (en) 2005-02-03
EP1651210A1 (en) 2006-05-03
RU2319508C2 (en) 2008-03-20
MXPA06001288A (en) 2006-04-11
RU2006101628A (en) 2006-08-27
KR20060031873A (en) 2006-04-13
AU2004258745A1 (en) 2005-02-03
JP2007500691A (en) 2007-01-18
IL172735A0 (en) 2006-04-10
KR100780983B1 (en) 2007-11-30
CN1829510A (en) 2006-09-06
ZA200600096B (en) 2007-02-28
CA2533101A1 (en) 2005-02-03
CO5650245A2 (en) 2006-06-30
NO20060982L (en) 2006-05-02

Similar Documents

Publication Publication Date Title
WO2005009436A8 (en) Dispersible formulation of an anti-inflammatory agent
WO2004082588A3 (en) Dispersible formulation of an anti-inflammatory agent
WO2005023227A3 (en) Nicotine formulations and use thereof
TWI265809B (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
NL350084I2 (en) Sedaxane and Fludioxonil
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004060345A3 (en) Dispersible pharmaceutical compositions
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2006010589A3 (en) Post foaming gel mousse
WO2005000241A8 (en) Compositons and methods for topical administration
AU8317498A (en) Fluoxetine pharmaceutical formulations
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2007123740A3 (en) Pharmaceutical compositions for promoting wound healing
WO2007044348A3 (en) Anti-infective hygiene products based on cellulose acetate phthalate
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
WO2005009472A3 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2008042557A3 (en) Formulation and method for a shampoo for animals

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022099.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2005 UNDER (72,75) THE ADDRESS OF "BURNS, JOHN, WILLIAM, II" SHOULD READ "812 4TH AVENUE #8, ANTIGO, WI 54409 (US)."

WWE Wipo information: entry into national phase

Ref document number: 544310

Country of ref document: NZ

Ref document number: 172735

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 05130971

Country of ref document: CO

Ref document number: 6136/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/00096

Country of ref document: ZA

Ref document number: 2004258745

Country of ref document: AU

Ref document number: 200600096

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2533101

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006500226

Country of ref document: PH

Ref document number: 1020067002034

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001288

Country of ref document: MX

Ref document number: 2006521702

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004258745

Country of ref document: AU

Date of ref document: 20040719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004258745

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004744112

Country of ref document: EP

Ref document number: 2006101628

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004744112

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412581

Country of ref document: BR